BE Ventures Leads AcroCyte Therapeutics’ US$10 Million Financing Round to Accelerate Clinical Translation of the R³CE® Platform and U.S. Expansion Read More »
From FDA Clearance to Organ Transplantation: ANIVIA’s U.S. Commercialization Pathway for Taiwan’s Therapeutic MedTech Read More »
After Passing Innovation Board Review, H2U Receives Investment from BE Health Ventures and Partners to Establish a Corporate Accelerator for Digital Health Read More »
Connecting Taiwan with Global Healthcare Innovation: TMU × BE × SCHS Demo Day Brings Together MedTech Startups from 7 Countries to Accelerate Clinical Validation and Cross-Border Collaboration Read More »
2026 TMU x BE x SCHS Demo Day Brings Together 10 MedTech Startups from 7 Countries, Focusing on Investment, Clinical Validation, and Cross-Border Business Partnerships Read More »
Congratulations to the BE PIM team – MedicalTek for successfully completing a RMB 120 million Series A funding round. Read More »
BE Ventures Leads AcroCyte Therapeutics’ US$10 Million Financing Round to Accelerate Clinical Translation of the R³CE® Platform and U.S. Expansion Read More »
From FDA Clearance to Organ Transplantation: ANIVIA’s U.S. Commercialization Pathway for Taiwan’s Therapeutic MedTech Read More »
After Passing Innovation Board Review, H2U Receives Investment from BE Health Ventures and Partners to Establish a Corporate Accelerator for Digital Health Read More »
Connecting Taiwan with Global Healthcare Innovation: TMU × BE × SCHS Demo Day Brings Together MedTech Startups from 7 Countries to Accelerate Clinical Validation and Cross-Border Collaboration Read More »
2026 TMU x BE x SCHS Demo Day Brings Together 10 MedTech Startups from 7 Countries, Focusing on Investment, Clinical Validation, and Cross-Border Business Partnerships Read More »
Congratulations to the BE PIM team – MedicalTek for successfully completing a RMB 120 million Series A funding round. Read More »
Article BE Ventures Leads AcroCyte Therapeutics’ US$10 Million Financing Round to Accelerate Clinical Translation of the R³CE® Platform and U.S. Expansion Read More » 2026年8月26日
Article From FDA Clearance to Organ Transplantation: ANIVIA’s U.S. Commercialization Pathway for Taiwan’s Therapeutic MedTech Read More » 2026年8月20日
Uncategorized After Passing Innovation Board Review, H2U Receives Investment from BE Health Ventures and Partners to Establish a Corporate Accelerator for Digital Health Read More » 2026年8月19日
